- RecruitingPHASE1
A Study of AZD0120 in Autoimmune Diseases
This study is looking at a new treatment called AZD0120 for certain long-term conditions like systemic sclerosis, inflammatory muscle diseases, and severe rheumatoid arthritis. It's an early-stage study to see how safe the treatment is and if people can tolerate it.
For: Systemic Sclerosis · Idiopathic Inflammatory Myopathies · Rheumatoid ArthritisUnited States · Australia · Germany - RecruitingPHASE1, PHASE2
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
This study is testing a new cell therapy (AZD0120) for people with AL amyloidosis that has come back or not responded to previous treatments. It aims to see how safe and effective the treatment is.
For: Relapsed AL Amyloidosis · Refractory AL Amyloidosis · Light Chain AmyloidosisUnited States · Canada · United Kingdom - RecruitingPHASE3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
This study compares a new treatment, AZD0120, with standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new medicine works better and is safe for patients.
For: Relapsed Refractory Multiple MyelomaUnited States · Australia · Brazil